Table of Contents

2019-2024 Global mRNA Vaccines & Therapeutics Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global mRNA Vaccines & Therapeutics Consumption 2014-2024
  • 2.1.2 mRNA Vaccines & Therapeutics Consumption CAGR by Region
• 2.2 mRNA Vaccines & Therapeutics Segment by Type
  • 2.2.1 Standardization Of Cancer Treatment MRNA Vaccine
  • 2.2.2 Individualized Cancer Treatment MRNA Vaccine
  • 2.2.3 Infectious Disease Treatment MRNA Vaccine
  • 2.2.4 Infection Prevention MRNA Vaccine
• 2.3 mRNA Vaccines & Therapeutics Consumption by Type
  • 2.3.1 Global mRNA Vaccines & Therapeutics Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global mRNA Vaccines & Therapeutics Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global mRNA Vaccines & Therapeutics Sale Price by Type (2014-2019)
• 2.4 mRNA Vaccines & Therapeutics Segment by Application
  • 2.4.1 Infectious Disease
  • 2.4.2 Cancer
  • 2.4.3 Other
• 2.5 mRNA Vaccines & Therapeutics Consumption by Application
  • 2.5.1 Global mRNA Vaccines & Therapeutics Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global mRNA Vaccines & Therapeutics Value and Market Share by Application (2014-2019)
  • 2.5.3 Global mRNA Vaccines & Therapeutics Sale Price by Application (2014-2019)

3 Global mRNA Vaccines & Therapeutics by Players

• 3.1 Global mRNA Vaccines & Therapeutics Sales Market Share by Players
  • 3.1.1 Global mRNA Vaccines & Therapeutics Sales by Players (2017-2019)
  • 3.1.2 Global mRNA Vaccines & Therapeutics Sales Market Share by Players (2017-2019)
• 3.2 Global mRNA Vaccines & Therapeutics Revenue Market Share by Players
  • 3.2.1 Global mRNA Vaccines & Therapeutics Revenue by Players (2017-2019)
  • 3.2.2 Global mRNA Vaccines & Therapeutics Revenue Market Share by Players (2017-2019)
• 3.3 Global mRNA Vaccines & Therapeutics Sale Price by Players
• 3.4 Global mRNA Vaccines & Therapeutics Manufacturing Base Distribution, Sales Area, Product Types by Players
  • 3.4.1 Global mRNA Vaccines & Therapeutics Manufacturing Base Distribution and Sales Area by Players
  • 3.4.2 Players mRNA Vaccines & Therapeutics Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 mRNA Vaccines & Therapeutics by Regions

• 4.1 mRNA Vaccines & Therapeutics by Regions
  • 4.1.1 Global mRNA Vaccines & Therapeutics Consumption by Regions
  • 4.1.2 Global mRNA Vaccines & Therapeutics Value by Regions
• 4.2 Americas mRNA Vaccines & Therapeutics Consumption Growth
• 4.3 APAC mRNA Vaccines & Therapeutics Consumption Growth
• 4.4 Europe mRNA Vaccines & Therapeutics Consumption Growth
• 4.5 Middle East & Africa mRNA Vaccines & Therapeutics Consumption Growth

5 Americas

• 5.1 Americas mRNA Vaccines & Therapeutics Consumption by Countries
  • 5.1.1 Americas mRNA Vaccines & Therapeutics Consumption by Countries (2014-2019)
  • 5.1.2 Americas mRNA Vaccines & Therapeutics Value by Countries (2014-2019)
• 5.2 Americas mRNA Vaccines & Therapeutics Consumption by Type
• 5.3 Americas mRNA Vaccines & Therapeutics Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC mRNA Vaccines & Therapeutics Consumption by Countries
  • 6.1.1 APAC mRNA Vaccines & Therapeutics Consumption by Countries (2014-2019)
  • 6.1.2 APAC mRNA Vaccines & Therapeutics Value by Countries (2014-2019)
• 6.2 APAC mRNA Vaccines & Therapeutics Consumption by Type
• 6.3 APAC mRNA Vaccines & Therapeutics Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe mRNA Vaccines & Therapeutics by Countries
  • 7.1.1 Europe mRNA Vaccines & Therapeutics Consumption by Countries (2014-2019)
  • 7.1.2 Europe mRNA Vaccines & Therapeutics Value by Countries (2014-2019)
• 7.2 Europe mRNA Vaccines & Therapeutics Consumption by Type
• 7.3 Europe mRNA Vaccines & Therapeutics Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa mRNA Vaccines & Therapeutics by Countries
  • 8.1.1 Middle East & Africa mRNA Vaccines & Therapeutics Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa mRNA Vaccines & Therapeutics Value by Countries (2014-2019)
• 8.2 Middle East & Africa mRNA Vaccines & Therapeutics Consumption by Type
• 8.3 Middle East & Africa mRNA Vaccines & Therapeutics Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Channels
  • 10.1.2 Indirect Channels
• 10.2 mRNA Vaccines & Therapeutics Distributors
• 10.3 mRNA Vaccines & Therapeutics Customer

11 Global mRNA Vaccines & Therapeutics Market Forecast

• 11.1 Global mRNA Vaccines & Therapeutics Consumption Forecast (2019-2024)
• 11.2 Global mRNA Vaccines & Therapeutics Forecast by Regions
  • 11.2.1 Global mRNA Vaccines & Therapeutics Forecast by Regions (2019-2024)
  • 11.2.2 Global mRNA Vaccines & Therapeutics Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global mRNA Vaccines & Therapeutics Forecast by Type
• 11.8 Global mRNA Vaccines & Therapeutics Forecast by Application

12 Key Players Analysis

• 12.1 Moderna Therapeutics
  • 12.1.1 Company Details
  • 12.1.2 mRNA Vaccines & Therapeutics Product Offered
  • 12.1.3 Moderna Therapeutics mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 Moderna Therapeutics News
• 12.2 CureVac
  • 12.2.1 Company Details
  • 12.2.2 mRNA Vaccines & Therapeutics Product Offered
  • 12.2.3 CureVac mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 CureVac News
• 12.3 Translate Bio
  • 12.3.1 Company Details
  • 12.3.2 mRNA Vaccines & Therapeutics Product Offered
  • 12.3.3 Translate Bio mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 Translate Bio News
• 12.4 BioNTech
  • 12.4.1 Company Details
  • 12.4.2 mRNA Vaccines & Therapeutics Product Offered
  • 12.4.3 BioNTech mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.4.4 Main Business Overview
  • 12.4.5 BioNTech News
• 12.5 Sangamo Therapeutics
  • 12.5.1 Company Details
  • 12.5.2 mRNA Vaccines & Therapeutics Product Offered
  • 12.5.3 Sangamo Therapeutics mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.5.4 Main Business Overview
  • 12.5.5 Sangamo Therapeutics News
• 12.6 Argos Therapeutics
  • 12.6.1 Company Details
  • 12.6.2 mRNA Vaccines & Therapeutics Product Offered
  • 12.6.3 Argos Therapeutics mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.6.4 Main Business Overview
  • 12.6.5 Argos Therapeutics News
• 12.7 In-Cell-Art
  • 12.7.1 Company Details
  • 12.7.2 mRNA Vaccines & Therapeutics Product Offered
  • 12.7.3 In-Cell-Art mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.7.4 Main Business Overview
  • 12.7.5 In-Cell-Art News
• 12.8 eTheRNA
  • 12.8.1 Company Details
  • 12.8.2 mRNA Vaccines & Therapeutics Product Offered
  • 12.8.3 eTheRNA mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.8.4 Main Business Overview
  • 12.8.5 eTheRNA News
• 12.9 Ethris
  • 12.9.1 Company Details
  • 12.9.2 mRNA Vaccines & Therapeutics Product Offered
  • 12.9.3 Ethris mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.9.4 Main Business Overview
  • 12.9.5 Ethris News
• 12.10 Tiba Biotechnology
  • 12.10.1 Company Details
  • 12.10.2 mRNA Vaccines & Therapeutics Product Offered
  • 12.10.3 Tiba Biotechnology mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.10.4 Main Business Overview
  • 12.10.5 Tiba Biotechnology News

13 Research Findings and Conclusion

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
mRNA Vaccines & Therapeutics is in the development stage and there is no use in the market. The fastest research is Clinical phrase II, such as AGS-004 of Argos Therapeutics, SB-FIX, SB-318, SB-913 of Sangamo Therapeutics. The major application of mRNA Vaccines & Therapeutics is for infectious disease, cancer and others. And infectious disease and cancer are the major applications.
Since the product still in development stage, so companies rely mainly on investment or cooperation to obtain funding to continue research and development.
The research of mRNA Vaccines & Therapeutics to treat infectious disease, cancer and others. The expenses on infectious disease is the most, with the market share of 46% in 2017.

According to this study, over the next five years the mRNA Vaccines & Therapeutics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in mRNA Vaccines & Therapeutics business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of mRNA Vaccines & Therapeutics market by product type, application, key manufacturers and key regions and countries.

This study considers the mRNA Vaccines & Therapeutics value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Standardization Of Cancer Treatment MRNA Vaccine
Individualized Cancer Treatment MRNA Vaccine
Infectious Disease Treatment MRNA Vaccine
Infection Prevention MRNA Vaccine
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Infectious Disease
Cancer
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global mRNA Vaccines & Therapeutics consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of mRNA Vaccines & Therapeutics market by identifying its various subsegments.
Focuses on the key global mRNA Vaccines & Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the mRNA Vaccines & Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of mRNA Vaccines & Therapeutics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.